MBP8298
Posted: Thu Oct 12, 2006 10:39 am
BioMS Medical expands pivotal multiple sclerosis trial into Finland
BioMS Medical Corp, a leading developer in the treatment of multiple sclerosis (MS), today announced it has received approval from the National Agency for Medicines to begin enrolling patients in Finland into its ongoing pivotal phase II/III trial of MBP8298, a proprietary synthetic peptide for the treatment of secondary progressive multiple sclerosis (SPMS).
"Based on the results we have generated to-date, MBP8298 appears to have the potential to fundamentally alter the course of this devastating disease," said Kevin Giese, President and CEO of BioMS. "We are pleased to be able to include patients from Finland in this important multi-national trial. The population in Finland suffers disproportionately from multiple sclerosis and like BioMS is committed to the development of an effective treatment."
Pivotal Phase II/III Multiple Sclerosis Trial
BioMS Medical is currently enrolling patients across Canada, the U.K., Germany, Sweden, the Netherlands, Spain, and Denmark in its pivotal Phase II/III clinical trial evaluating MBP8298 for the treatment of secondary progressive multiple sclerosis (SPMS). The trial is a randomised, double-blind study enrolling approximately 553 patients who will be administered either MBP8298 or placebo intravenously every six months for a period of two years. The primary clinical endpoint for the trial is defined as a statistically and clinically significant increase in the time to progression of the disease as measured by the Expanded Disability Status Scale (EDSS), in patients with HLA-DR2 and/or HLA-DR4 immune response genes. Time to disease progression in patients with other HLA-DR types will be assessed separately as an exploratory arm of the same study. To date the trial has successfully passed five safety reviews by its independent Data Safety Monitoring Board.
Source: BioMS Medical Corp.
BioMS Medical Corp, a leading developer in the treatment of multiple sclerosis (MS), today announced it has received approval from the National Agency for Medicines to begin enrolling patients in Finland into its ongoing pivotal phase II/III trial of MBP8298, a proprietary synthetic peptide for the treatment of secondary progressive multiple sclerosis (SPMS).
"Based on the results we have generated to-date, MBP8298 appears to have the potential to fundamentally alter the course of this devastating disease," said Kevin Giese, President and CEO of BioMS. "We are pleased to be able to include patients from Finland in this important multi-national trial. The population in Finland suffers disproportionately from multiple sclerosis and like BioMS is committed to the development of an effective treatment."
Pivotal Phase II/III Multiple Sclerosis Trial
BioMS Medical is currently enrolling patients across Canada, the U.K., Germany, Sweden, the Netherlands, Spain, and Denmark in its pivotal Phase II/III clinical trial evaluating MBP8298 for the treatment of secondary progressive multiple sclerosis (SPMS). The trial is a randomised, double-blind study enrolling approximately 553 patients who will be administered either MBP8298 or placebo intravenously every six months for a period of two years. The primary clinical endpoint for the trial is defined as a statistically and clinically significant increase in the time to progression of the disease as measured by the Expanded Disability Status Scale (EDSS), in patients with HLA-DR2 and/or HLA-DR4 immune response genes. Time to disease progression in patients with other HLA-DR types will be assessed separately as an exploratory arm of the same study. To date the trial has successfully passed five safety reviews by its independent Data Safety Monitoring Board.
Source: BioMS Medical Corp.